Speaker illustration

Miss Megan Yee

Boston (United States of America)

Characterization of major and clinically relevant non-major bleeding in the APEX trial

Event: ESC Congress 2018

Topic: Anticoagulants

Session: Oral anticoagulants : news from large trials and registries

Thumbnail

Betrixaban compared to enoxaparin among obese acute medically ill subjects: an APEX trial subgroup analysis

Event: ESC Congress 2018

Topic: Obesity

Session: Obesity and cardiovascular disease

Thumbnail

History of venous thromboembolism is associated with higher risk for recurrent venous thromboembolism: insights from the APEX trial

Event: ESC CONGRESS 2017

Topic: Thrombosis and coagulation

Session: Latest on STEMI

Thumbnail

Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy

Event: ESC CONGRESS 2017

Topic: Atrial fibrillation (AF)

Session: Bleeding and LAA occlusion

Thumbnail

Direct ugmentation of cholesterol efflux capacity in AMI atients: a PKPD substudy of AEGIS-I

Event: ESC CONGRESS 2017

Topic: Pharmacology

Session: Inflammation, diabetes and their influence on the heart

Thumbnail

This platform is supported by

logo Novo Nordisk